Chromatic visual evoked potentials in young patients with demyelinating disease

Effect of brimonidine on visual indices in patients with acute optic neuritis: A single blind randomized clinical trial

PURPOSE

This study investigates brimonidine's potential effect on visual functions, particularly contrast sensitivity (CS), an indicator of retinal ganglion cell function.

METHODS

In this single-blind, randomized clinical trial, 60 patients (aged 23-56) with first-episode acute optic neuritis within seven days of symptom onset were randomly assigned to brimonidine or control groups. The intervention group received brimonidine three times daily for three months, while the control group received synthetic tears with the same dosage and frequency. Primary outcomes were changes in CS, visual acuity (VA), and color vision at one and three months post-treatment. Repeated measures ANOVA was used to assess statistically significant and partial eta squared (η2) values, mean differences, and clinically significance important were reported.

RESULTS

All participants completed the study without complications. VA improved significantly in both groups by follow-up end (p < 0.001), with significant improvement from first to third month only in the brimonidine group (p < 0.001). The mean VA difference between groups was not statistically and clinically significant. CS showed statistically significant improvement within both groups (p < 0.001) and between groups (p < 0.001), with a large effect size (partial η2 = 0.28). The mean CS difference between groups (14.5) was clinically considerable. No significant changes in color vision were observed between groups (p = 0.96).

CONCLUSION

Brimonidine significantly improved contrast sensitivity compared to placebo and was well-tolerated. Its neuroprotective effects suggest it may be beneficial in treating optic neuritis and preserving retinal ganglion cell function.

TRIAL REGISTRATION

Prospectively registered at Iranian Clinical Trial Registration; Registration date 3 December 2022; Registration number: IRCT20221127056631N1.

Chromatic visual evoked potentials indicate early dysfunction of color processing in young patients with demyelinating disease

PURPOSE

Chromatic visual evoked potentials (cVEP) primarily reflect the parvocellular visual pathway function, which has been shown to be predominantly affected in demyelinating disease (DD). The purpose of this study was to evaluate cVEP responses and to compare them with other structural and functional findings in young patients with DD.

METHODS

Thirty patients (8-28 years of age) with DD with or without a history of optic neuritis (ON) were investigated. Twenty-five eyes had at least one episode of ON (ON-group) and 35 eyes had no clinically evident episode of ON (nON-group). OCT imaging was performed using a high-resolution spectral-domain OCT (SD-OCT), measuring retinal nerve fiber layer (RNFL) thickness. Pattern reversal electroretinography (PERG) and visual evoked potentials (VEP) were recorded according to the ISCEV standard, and chromatic visual evoked potentials (cVEP) were recorded to isoluminant red-green (R-G) and blue-yellow (B-Y) 7° circle stimuli, composed of horizontal sinusoidal gratings with spatial frequency 2 cycles/°, 90% chromatic contrast and onset-offset (300:700 ms) mode of stimulation. Structural and functional measures were analyzed and compared between the groups.

RESULTS

Both general (G) and temporal (T) RNFL thicknesses were reduced below normal limits in most of the eyes. However, in the ON-group (G: 77.5 ± 20.6, T: 51.4 ± 23.4 µm), the thinning was more significant (p < 0.001) than in the nON-group (G: 95.4 ± 12.1, T: 70.1 ± 11.5 µm). PERG N95 was within normal limits in the nON-group, while it was significantly more affected in the ON-group (7.4 ± 1.0 vs. 5.1 ± 2.0 μV; p < 0.0001). Similarly, also VEP P100 latency and amplitude showed a greater percentage of abnormality in the ON-group, the latency being longer (117.2 ± 16.9 vs. 99.4 ± 4.6 ms; p < 0.0001) and the amplitude lower (9.1 ± 5.1 vs. 16.4 ± 7.5 μV; p < 0.0001). The cVEP N-wave amplitude to R-G and B-Y stimuli was reduced below normal limits in both ON- and nON-groups; however, cVEP to B-Y stimulation were slightly more affected in the ON-group (4.0 ± 3.8 vs. 5.9 ± 3.3 µm; p = 0.02). A positive correlation between cVEP amplitude and RNFL thickness and between cVEP amplitude and PERG N95 amplitude, as well as a strong negative correlation between cVEP amplitude and P100 latency was observed.

CONCLUSIONS

These findings demonstrate that cVEP indicate early abnormality of parvocellular pathway function in eyes with or without a history of optic neuritis and can be used together with other structural and functional parameters to evaluate visual pathway integrity of young patients with DD.